TGRX-326

· Shenzhen TargetRx Co., Ltd.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for TGRX-326, covering 2024-06-27 to 2025-05-18. Get the full timeline:

Most recent: Clinical Trial Update: TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 1]